Bellier, Justine ; Université de Liège - ULiège > Cancer-Metastases Research Laboratory
Nokin, Marie-Julie ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases
Lardé, Eva ; Université de Liège - ULiège > Cancer-Metastases Research Laboratory
Karoyan, Philippe
Peulen, Olivier ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire
Bellahcene, Akeila ; Université de Liège - ULiège > Cancer-Metastases Research Laboratory
Language :
English
Title :
Methylglyoxal, a potent inducer of AGEs, connects between diabetes and cancer
Cho, N.H., Shaw, J.E., Karuranga, S., Huang, Y., da Rocha Fernandes, J.D., Ohlrogge, A.W., et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138 (2018), 271–281.
Johnson, J.A., Carstensen, B., Witte, D., Bowker, S.L., Lipscombe, L., Renehan, A.G., Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55 (2012), 1607–1618.
Renehan, A.G., Yeh, H.C., Johnson, J.A., Wild, S.H., Gale, E.A., Moller, H., Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55 (2012), 1619–1632.
Giovannucci, E., Harlan, D.M., Archer, M.C., Bergenstal, R.M., Gapstur, S.M., Habel, L.A., et al. Diabetes and cancer: a consensus report. Diabetes Care 33 (2010), 1674–1685.
Graff, R.E., Sanchez, A., Tobias, D.K., Rodriguez, D., Barrisford, G.W., Blute, M.L., et al. Type 2 diabetes in relation to the risk of renal cell carcinoma among men and women in two large prospective cohort studies. Diabetes Care 41 (2018), 1432–1437.
Kasper, J.S., Giovannucci, E., A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 (2006), 2056–2062.
Bansal, D., Bhansali, A., Kapil, G., Undela, K., Tiwari, P., Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis, 16(151–8), 2013, s1.
Bensimon, L., Yin, H., Suissa, S., Pollak, M.N., Azoulay, L., Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Cont 25 (2014), 329–338.
Barone, B.B., Yeh, H.C., Snyder, C.F., Peairs, K.S., Stein, K.B., Derr, R.L., et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300 (2008), 2754–2764.
Ryu, T.Y., Park, J., Scherer, P.E., Hyperglycemia as a risk factor for cancer progression. Diabetes Metabol J 38 (2014), 330–336.
Cignarelli, A., Genchi, V.A., Caruso, I., Natalicchio, A., Perrini, S., Laviola, L., et al. Diabetes and cancer: pathophysiological fundamentals of a ‘dangerous affair’. Diabetes Res Clin Pract, 2018.
Pirola, L., Balcerczyk, A., Okabe, J., El-Osta, A., Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 6 (2010), 665–675.
Park, J., Sarode, V.R., Euhus, D., Kittler, R., Scherer, P.E., Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer. Proc Natl Acad Sci USA 109 (2012), 21058–21063.
Duncan, B.B., Schmidt, M.I., The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes. Diabetes Technol Ther 8 (2006), 7–17.
Crusz, S.M., Balkwill, F.R., Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12 (2015), 584–596.
Todoric, J., Antonucci, L., Karin, M., Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila) 9 (2016), 895–905.
Berg, T.J., Snorgaard, O., Faber, J., Torjesen, P.A., Hildebrandt, P., Mehlsen, J., et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22 (1999), 1186–1190.
Kilhovd, B.K., Berg, T.J., Birkeland, K.I., Thorsby, P., Hanssen, K.F., Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22 (1999), 1543–1548.
Manley, S., Haemoglobin A1c–a marker for complications of type 2 diabetes: the experience from the UK prospective diabetes study (UKPDS). Clin Chem Lab Med 41 (2003), 1182–1190.
Koenig, R.J., Peterson, C.M., Jones, R.L., Saudek, C., Lehrman, M., Cerami, A., Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. New England J Med 295 (1976), 417–420.
Neeper, M., Schmidt, A.M., Brett, J., Yan, S.D., Wang, F., Pan, Y.C., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267 (1992), 14998–15004.
Bierhaus, A., Nawroth, P.P., Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52 (2009), 2251–2263.
Sparvero, L.J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Translat Med, 7, 2009, 17.
Kwak, T., Drews-Elger, K., Ergonul, A., Miller, P.C., Braley, A., Hwang, G.H., et al. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene 36 (2017), 1559–1572.
Richard, J.P., Mechanism for the formation of methylglyoxal from triosephosphates. Biochem Soc Trans 21 (1993), 549–553.
Phillips, S.A., Thornalley, P.J., The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 212 (1993), 101–105.
Thornalley, P.J., Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification–a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 27 (1996), 565–573.
Thornalley, P.J., Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems–role in ageing and disease. Drug Metabol Drug Interact 23 (2008), 125–150.
Thornalley, P.J., Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J 254 (1988), 751–755.
Thornalley, P.J., The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 269 (1990), 1–11.
Vander Jagt, D.L., Hunsaker, L.A., Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chem Biol Interact 143–144 (2003), 341–351.
Lee, J.Y., Song, J., Kwon, K., Jang, S., Kim, C., Baek, K., et al. Human DJ-1 and its homologs are novel glyoxalases. Hum Mol Genet 21 (2012), 3215–3225.
Richarme, G., Mihoub, M., Dairou, J., Bui, L.C., Leger, T., Lamouri, A., Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues. J Biol Chem 290 (2015), 1885–1897.
Thornalley, P.J., Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci 1043 (2005), 111–117.
Rabbani, N., Thornalley, P.J., Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. Nat Protoc 9 (2014), 1969–1979.
Rabbani, N., Thornalley, P.J., The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann N Y Acad Sci 1126 (2008), 124–127.
Thornalley, P.J., Battah, S., Ahmed, N., Karachalias, N., Agalou, S., Babaei-Jadidi, R., et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375 (2003), 581–592.
Odani, H., Shinzato, T., Matsumoto, Y., Usami, J., Maeda, K., Increase in three alpha, beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 256 (1999), 89–93.
Brownlee, M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005), 1615–1625.
Nakayama, K., Nakayama, M., Iwabuchi, M., Terawaki, H., Sato, T., Kohno, M., et al. Plasma alpha-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. Am J Nephrol 28 (2008), 871–878.
Bellahcene, A., Nokin, M.J., Castronovo, V., Schalkwijk, C., Methylglyoxal-derived stress: an emerging biological factor involved in the onset and progression of cancer. Semin Cancer Biol 49 (2018), 64–74.
Dobler, D., Ahmed, N., Song, L., Eboigbodin, K.E., Thornalley, P.J., Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 55 (2006), 1961–1969.
Pedchenko, V.K., Chetyrkin, S.V., Chuang, P., Ham, A.J., Saleem, M.A., Mathieson, P.W., et al. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 54 (2005), 2952–2960.
Pickup, M.W., Mouw, J.K., Weaver, V.M., The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 15 (2014), 1243–1253.
Liberti, M.V., Locasale, J.W., The Warburg effect: how does it benefit cancer cells?. Trends Biochem Sci 41 (2016), 211–218.
van Heijst, J.W., Niessen, H.W., Hoekman, K., Schalkwijk, C.G., Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. Ann N Y Acad Sci 1043 (2005), 725–733.
Chiavarina, B., Nokin, M.J., Durieux, F., Bianchi, E., Turtoi, A., Peulen, O., et al. Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget 5 (2014), 5472–5482.
Chiavarina, B., Nokin, M.J., Bellier, J., Durieux, F., Bletard, N., Sherer, F., et al. Methylglyoxal-mediated stress correlates with high metabolic activity and promotes tumor growth in colorectal cancer. Int J Mol Sci, 18, 2017.
Apple, M.A., Greenberg, D.M., Inhibition of cancer growth in mice by a normal metabolite. Life Sci 6 (1967), 2157–2160.
Jerzykowski, T., Matuszewski, W., Otrzonsek, N., Winter, R., Antineoplastic action of methylglyoxal. Neoplasma 17 (1970), 25–35.
Conroy, P.J., Carcinostatic activity of methylglyoxal and related substances in tumour-bearing mice. Ciba Found Symp, 271–300, 1978.
Egyud, L.G., Szent-Gyorgyi, A., Cancerostatic action of methylglyoxal. Science, 160, 1968, 1140.
Santarius, T., Shipley, J., Brewer, D., Stratton, M.R., Cooper, C.S., A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 10 (2010), 59–64.
Lo, T.W., Thornalley, P.J., Inhibition of proliferation of human leukaemia 60 cells by diethyl esters of glyoxalase inhibitors in vitro. Biochem Pharmacol 44 (1992), 2357–2363.
Thornalley, P.J., Edwards, L.G., Kang, Y., Wyatt, C., Davies, N., Ladan, M.J., et al. Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem Pharmacol 51 (1996), 1365–1372.
Sakamoto, H., Mashima, T., Sato, S., Hashimoto, Y., Yamori, T., Tsuruo, T., Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 7 (2001), 2513–2518.
Guo, Y., Zhang, Y., Yang, X., Lu, P., Yan, X., Xiao, F., et al. Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2. Cancer Biol Ther 17 (2016), 169–180.
Loarca, L., Sassi-Gaha, S., Artlett, C.M., Two alpha-dicarbonyls downregulate migration, invasion, and adhesion of liver cancer cells in a p53-dependent manner. Dig Liver Dis 45 (2013), 938–946.
Chen, Y., Fang, L., Li, G., Zhang, J., Li, C., Ma, M., et al. Synergistic inhibition of colon cancer growth by the combination of methylglyoxal and silencing of glyoxalase I mediated by the STAT1 pathway. Oncotarget 8 (2017), 54838–54857.
Jandial, R., Neman, J., Lim, P.P., Tamae, D., Kowolik, C.M., Wuenschell, G.E., et al. Inhibition of GLO1 in glioblastoma multiforme increases DNA-AGEs, stimulates RAGE expression, and inhibits brain tumor growth in orthotopic mouse models. Int J Mol Sci, 19, 2018.
Amicarelli, F., Colafarina, S., Cattani, F., Cimini, A., Di Ilio, C., Ceru, M.P., et al. Scavenging system efficiency is crucial for cell resistance to ROS-mediated methylglyoxal injury. Free Radic Biol Med 35 (2003), 856–871.
Speer, O., Morkunaite-Haimi, S., Liobikas, J., Franck, M., Hensbo, L., Linder, M.D., et al. Rapid suppression of mitochondrial permeability transition by methylglyoxal. Role of reversible arginine modification. J Biol Chem 278 (2003), 34757–34763.
Belanger, M., Yang, J., Petit, J.M., Laroche, T., Magistretti, P.J., Allaman, I., Role of the glyoxalase system in astrocyte-mediated neuroprotection. J Neurosci 31 (2011), 18338–18352.
Vulesevic, B., McNeill, B., Giacco, F., Maeda, K., Blackburn, N.J., Brownlee, M., et al. Methylglyoxal-induced endothelial cell loss and inflammation contribute to the development of diabetic cardiomyopathy. Diabetes 65 (2016), 1699–1713.
Zender, L., Xue, W., Zuber, J., Semighini, C.P., Krasnitz, A., Ma, B., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135 (2008), 852–864.
Mattson, M.P., Hormesis defined. Ageing Res Rev 7 (2008), 1–7.
Nokin, M.J., Durieux, F., Bellier, J., Peulen, O., Uchida, K., Spiegel, D.A., et al. Hormetic potential of methylglyoxal, a side-product of glycolysis, in switching tumours from growth to death. Sci Rep, 7, 2017, 11722.
Nokin, M.J., Durieux, F., Peixoto, P., Chiavarina, B., Peulen, O., Blomme, A., et al. Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. Elife, 2016, 5.
Lin, J.A., Wu, C.H., Yen, G.C., Methylglyoxal displays colorectal cancer-promoting properties in the murine models of azoxymethane and CT26 isografts. Free Radic Biol Med 115 (2018), 436–446.
Wang, X., Chen, M., Zhou, J., Zhang, X., HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review). Int J Oncol 45 (2014), 18–30.
Gruden, G., Bruno, G., Chaturvedi, N., Burt, D., Schalkwijk, C., Pinach, S., et al. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: a novel circulating marker for diabetic neuropathy. Diabetes 57 (2008), 1966–1970.
Jakhotia, S., Sivaprasad, M., Shalini, T., Reddy, P.Y., Viswanath, K., Jakhotia, K., et al. Circulating levels of Hsp27 in microvascular complications of diabetes: Prospects as a biomarker of diabetic nephropathy. J Diabetes Compl 32 (2018), 221–225.
van Heijst, J.W., Niessen, H.W., Musters, R.J., van Hinsbergh, V.W., Hoekman, K., Schalkwijk, C.G., Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis. Cancer Lett 241 (2006), 309–319.
Oya-Ito, T., Naito, Y., Takagi, T., Handa, O., Matsui, H., Yamada, M., et al. Heat-shock protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer. Biochim Biophys Acta 1812 (2011), 769–781.
Bair, W.B. 3rd, Cabello, C.M., Uchida, K., Bause, A.S., Wondrak, G.T., GLO1 overexpression in human malignant melanoma. Melanoma Res 20 (2010), 85–96.
Sakamoto, H., Mashima, T., Yamamoto, K., Tsuruo, T., Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J Biol Chem 277 (2002), 45770–45775.
Trepel, J., Mollapour, M., Giaccone, G., Neckers, L., Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10 (2010), 537–549.
Smith, U., Gale, E.A., Does diabetes therapy influence the risk of cancer?. Diabetologia 52 (2009), 1699–1708.
Pernicova, I., Korbonits, M., Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10 (2014), 143–156.
Noh, Y., Jeon, S.M., Shin, S., Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy. Int J Cancer, 2018.
Heckman-Stoddard, B.M., DeCensi, A., Sahasrabuddhe, V.V., Ford, L.G., Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 60 (2017), 1639–1647.
Li, M., Li, X., Zhang, H., Lu, Y., Molecular mechanisms of metformin for diabetes and cancer treatment. Front Physiol, 9, 2018, 1039.
Kinsky, O.R., Hargraves, T.L., Anumol, T., Jacobsen, N.E., Dai, J., Snyder, S.A., et al. Metformin scavenges methylglyoxal to form a novel imidazolinone metabolite in humans. Chem Res Toxicol 29 (2016), 227–234.
Janssen, B., Hohenadel, D., Brinkkoetter, P., Peters, V., Rind, N., Fischer, C., et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 54 (2005), 2320–2327.
Albrecht, T., Schilperoort, M., Zhang, S., Braun, J.D., Qiu, J., Rodriguez, A., et al. Carnosine attenuates the development of both type 2 diabetes and diabetic nephropathy in BTBR ob/ob mice. Sci Rep, 7, 2017, 44492.
Pfister, F., Riedl, E., Wang, Q., vom Hagen, F., Deinzer, M., Harmsen, M.C., et al. Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. Cell Physiol Biochem 28 (2011), 125–136.
Boldyrev, A.A., Aldini, G., Derave, W., Physiology and pathophysiology of carnosine. Physiol Rev 93 (2013), 1803–1845.
Hipkiss, A.R., Carnosine, a protective, anti-ageing peptide?. Int J Biochem Cell Biol 30 (1998), 863–868.
Weigand, T., Singler, B., Fleming, T., Nawroth, P., Klika, K.D., Thiel, C., et al. Carnosine catalyzes the formation of the oligo/polymeric products of methylglyoxal. Cell Physiol Biochem 46 (2018), 713–726.
Iovine, B., Oliviero, G., Garofalo, M., Orefice, M., Nocella, F., Borbone, N., et al. The anti-proliferative effect of L-carnosine correlates with a decreased expression of hypoxia inducible factor 1 alpha in human colon cancer cells. PLoS ONE, 9, 2014, e96755.
Shen, Y., Yang, J., Li, J., Shi, X., Ouyang, L., Tian, Y., et al. Carnosine inhibits the proliferation of human gastric cancer SGC-7901 cells through both of the mitochondrial respiration and glycolysis pathways. PLoS ONE, 9, 2014, e104632.
Zhang, Z., Miao, L., Wu, X., Liu, G., Peng, Y., Xin, X., et al. Carnosine inhibits the proliferation of human gastric carcinoma cells by retarding Akt/mTOR/p70S6K signaling. J Cancer 5 (2014), 382–389.
Oppermann, H., Dietterle, J., Purcz, K., Morawski, M., Eisenloffel, C., Muller, W., et al. Carnosine selectively inhibits migration of IDH-wildtype glioblastoma cells in a co-culture model with fibroblasts. Cancer Cell Int, 18, 2018, 111.
Garofalo, M., Iovine, B., Kuryk, L., Capasso, C., Hirvinen, M., Vitale, A., et al. Oncolytic adenovirus loaded with L-carnosine as novel strategy to enhance the antitumor activity. Mol Cancer Ther 15 (2016), 651–660.
Zhang, D.W., Fu, M., Gao, S.H., Liu, J.L., Curcumin and diabetes: a systematic review. Evid Based Complement Alternat Med, 2013, 2013, 636053.
Hatcher, H., Planalp, R., Cho, J., Torti, F.M., Torti, S.V., Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65 (2008), 1631–1652.
Sullivan, L.B., Gui, D.Y., Vander Heiden, M.G., Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer 16 (2016), 680–693.
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., Vigneri, R., Diabetes and cancer. Endocr Relat Cancer 16 (2009), 1103–1123.
Ahmed, N., Dobler, D., Dean, M., Thornalley, P.J., Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 280 (2005), 5724–5732.
Gao, Y., Wang, Y., Site-selective modifications of arginine residues in human hemoglobin induced by methylglyoxal. Biochemistry 45 (2006), 15654–15660.
Gangadhariah, M.H., Wang, B., Linetsky, M., Henning, C., Spanneberg, R., Glomb, M.A., et al. Hydroimidazolone modification of human alphaA-crystallin: effect on the chaperone function and protein refolding ability. Biochim Biophys Acta 1802 (2010), 432–441.
Thangarajah, H., Yao, D., Chang, E.I., Shi, Y., Jazayeri, L., Vial, I.N., et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 106 (2009), 13505–13510.
Queisser, M.A., Yao, D., Geisler, S., Hammes, H.P., Lochnit, G., Schleicher, E.D., et al. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 59 (2010), 670–678.
Schalkwijk, C.G., van Bezu, J., van der Schors, R.C., Uchida, K., Stehouwer, C.D., van Hinsbergh, V.W., Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett 580 (2006), 1565–1570.
Chang, T., Wang, R., Olson, D.J., Mousseau, D.D., Ross, A.R., Wu, L., Modification of Akt1 by methylglyoxal promotes the proliferation of vascular smooth muscle cells. FASEB J 25 (2011), 1746–1757.
Lee, H.J., Howell, S.K., Sanford, R.J., Beisswenger, P.J., Methylglyoxal can modify GAPDH activity and structure. Ann N Y Acad Sci 1043 (2005), 135–145.
Moraru, A., Wiederstein, J., Pfaff, D., Fleming, T., Miller, A.K., Nawroth, P., et al. Elevated levels of the reactive metabolite methylglyoxal recapitulate progression of type 2 diabetes. Cell Metab, 27(926–34), 2018, e8.
Cantero, A.V., Portero-Otin, M., Ayala, V., Auge, N., Sanson, M., Elbaz, M., et al. Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis. FASEB J 21 (2007), 3096–3106.
Mohamad, N.A., Cricco, G.P., Sambuco, L.A., Croci, M., Medina, V.A., Gutierrez, A.S., et al. Aminoguanidine impedes human pancreatic tumor growth and metastasis development in nude mice. World J Gastroenterol 15 (2009), 1065–1071.
Wang, G.Y., Ji, B., Wang, X., Gu, J.H., Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer. World J Gastroenterol 11 (2005), 3830–3833.
Colzani, M., De Maddis, D., Casali, G., Carini, M., Vistoli, G., Aldini, G., Reactivity, selectivity, and reaction mechanisms of aminoguanidine, hydralazine, pyridoxamine, and carnosine as sequestering agents of reactive carbonyl species: a comparative study. ChemMedChem 11 (2016), 1778–1789.
Miyata, T., van Ypersele de Strihou, C., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13 (2002), 2478–2487.
Sun, H., Li, T., Zhuang, R., Cai, W., Zheng, Y., Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: evidence from a meta-analysis including 55 studies. Medicine (Baltimore), 96, 2017, e6394.
Balan, B.J., Demkow, U., Skopinski, P., Bychawska, M., Skopinska-Rozewska, E., Lewicki, S., et al. The effect of pentoxifylline on L-1 sarcoma tumor growth and angiogenesis in Balb/c mice. Cent Eur J Immunol 42 (2017), 131–139.
Golunski, G., Woziwodzka, A., Piosik, J., Potential Use of pentoxifylline in cancer therapy. Curr Pharm Biotechnol 19 (2018), 206–216.
Rahbar, S., Natarajan, R., Yerneni, K., Scott, S., Gonzales, N., Nadler, J.L., Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 301 (2000), 65–77.
Vissers, M.C.M., Das, A.B., Potential mechanisms of action for vitamin C in cancer: reviewing the evidence. Front Physiol, 9, 2018, 809.
Sharma, C., Kaur, A., Thind, S.S., Singh, B., Raina, S., Advanced glycation End-products (AGEs): an emerging concern for processed food industries. J Food Sci Technol 52 (2015), 7561–7576.
Constantinou, C., Papas, A., Constantinou, A.I., Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 123 (2008), 739–752.
Komatsu, S., Yanaka, N., Matsubara, K., Kato, N., Antitumor effect of vitamin B6 and its mechanisms. Biochim Biophys Acta 1647 (2003), 127–130.
Booth, A.A., Khalifah, R.G., Hudson, B.G., Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 220 (1996), 113–119.
Nagaraj, R.H., Sarkar, P., Mally, A., Biemel, K.M., Lederer, M.O., Padayatti, P.S., Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys 402 (2002), 110–119.
Thun, M.J., Henley, S.J., Patrono, C., Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002), 252–266.
